Profil
Ed Gemo est directeur de l'information et vice-président principal de Turning Point Therapeutics, Inc. Dans le passé, M. Gemo a occupé le poste de directeur de l'information et de la sécurité, vice-président chez Halozyme Therapeutics, Inc, directeur de l'information et vice-président chez Onyx Pharmaceuticals, Inc et directeur de l'information et vice-président principal chez InterMune, Inc. Il a obtenu un diplôme de premier cycle au Brooklyn College et un MBA à la Pace University.
Postes actifs de Ed Gemo
| Sociétés | Poste | Début |
|---|---|---|
| TURG POIN | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Ed Gemo
| Sociétés | Poste | Fin |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2020 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | - |
| INTERMUNE INC | Chief Tech/Sci/R&D Officer | - |
Formation de Ed Gemo
| Brooklyn College | Undergraduate Degree |
| Pace University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
